TY - JOUR
T1 - Arginase
T2 - A multifaceted enzyme important in health and disease
AU - Caldwell, R. William
AU - Rodriguez, Paulo C.
AU - Toque, Haroldo A.
AU - Priya Narayanan, S.
AU - Caldwell, Ruth B.
N1 - Funding Information:
This work was supported by National Heart, Lung, and Blood Institute Grant RO1HL070215 (to R. W. Caldwell), National Eye Institute Grant RO1EY011766 (to R. B. Caldwell and R. W. Caldwell), National Cancer Institute Grant RO1CA18485 (to P. C. Rodriguez), American Heart Association Grants 13SDG174100007 (to H. A. Toque) and 11SDG7440088 (to S. P. Narayanan), and United States Department of Veterans Affairs Grant I01BX003221 (to R. B. Caldwell). R. B. Caldwell is the recipient of a Research Career Scientist Award from the Department of Veterans Affairs.
Publisher Copyright:
© 2018 American Physiological Society. All rights reserved.
PY - 2018/4
Y1 - 2018/4
N2 - The arginase enzyme developed in early life forms and was maintained during evolution. As the last step in the urea cycle, arginase cleaves L-arginine to form urea and L-ornithine. The urea cycle provides protection against excess ammonia, while L-ornithine is needed for cell proliferation, collagen formation, and other physiological functions. In mammals, increases in arginase activity have been linked to dysfunction and pathologies of the cardiovascular system, kidney, and central nervous system and also to dysfunction of the immune system and cancer. Two important aspects of the excessive activity of arginase may be involved in diseases. First, overly active arginase can reduce the supply of L-arginine needed for the production of nitric oxide (NO) by NO synthase. Second, too much L-ornithine can lead to structural problems in the vasculature, neuronal toxicity, and abnormal growth of tumor cells. Seminal studies have demonstrated that increased formation of reactive oxygen species and key inflammatory mediators promote this pathological elevation of arginase activity. Here, we review the involvement of arginase in diseases affecting the cardiovascular, renal, and central nervous system and cancer and discuss the value of therapies targeting the elevated activity of arginase.
AB - The arginase enzyme developed in early life forms and was maintained during evolution. As the last step in the urea cycle, arginase cleaves L-arginine to form urea and L-ornithine. The urea cycle provides protection against excess ammonia, while L-ornithine is needed for cell proliferation, collagen formation, and other physiological functions. In mammals, increases in arginase activity have been linked to dysfunction and pathologies of the cardiovascular system, kidney, and central nervous system and also to dysfunction of the immune system and cancer. Two important aspects of the excessive activity of arginase may be involved in diseases. First, overly active arginase can reduce the supply of L-arginine needed for the production of nitric oxide (NO) by NO synthase. Second, too much L-ornithine can lead to structural problems in the vasculature, neuronal toxicity, and abnormal growth of tumor cells. Seminal studies have demonstrated that increased formation of reactive oxygen species and key inflammatory mediators promote this pathological elevation of arginase activity. Here, we review the involvement of arginase in diseases affecting the cardiovascular, renal, and central nervous system and cancer and discuss the value of therapies targeting the elevated activity of arginase.
UR - http://www.scopus.com/inward/record.url?scp=85043571406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85043571406&partnerID=8YFLogxK
U2 - 10.1152/physrev.00037.2016
DO - 10.1152/physrev.00037.2016
M3 - Review article
C2 - 29412048
AN - SCOPUS:85043571406
SN - 0031-9333
VL - 98
SP - 641
EP - 665
JO - Physiological Reviews
JF - Physiological Reviews
IS - 2
ER -